中国民康医学
中國民康醫學
중국민강의학
MEDICAL JOURNAL OF CHINSEE PEOPLE HEALTH
2015年
8期
7-8,39
,共3页
α2/D2 受体拮抗力的平衡%米氮平%奋乃静%利培酮%添加治疗
α2/D2 受體拮抗力的平衡%米氮平%奮迺靜%利培酮%添加治療
α2/D2 수체길항력적평형%미담평%강내정%리배동%첨가치료
Balance between α2/D2 receptor antagonism%Mirtazapine%Perphenazine%Risperidone%Augmentative treatment
目的：：探求米氮平联合不同抗精神病药物治疗稳定期精神分裂症患者的结果。方法：将72例用利培酮( n=36)或奋乃静( n=36)治疗疗效欠佳的稳定期精神分裂症患者分别添加米氮平治疗12周,治疗期间用阳性和阴性症状量表(PANSS)和临床整体印象严重程度量表( CGI-S)评价患者的临床疗效,用副反应量表评价患者的不良反应( TESS)。结果：至12周末,米氮平联合利培酮或奋乃静可显著改善患者的PANSS总量表分(PANSS-T),PANSS阳性症状分量表分(PANSS-P)和PANSS阴性症状分量表分(PANSS-N),效应量(ES)分别为1.0、0.8和0.8。但治疗6周后,前者对患者的阳性症状改善不明显(P>0.05),后者对患者的阴性症状改善不明显(P>0.05)。两组患者的不良反应相似。结论：米氮平联合利培酮对患者的阴性症状改善明显,联合奋乃静对患者的阳性症状改善较明显,这一结果仍需大量的随机双盲研究确定。
目的：：探求米氮平聯閤不同抗精神病藥物治療穩定期精神分裂癥患者的結果。方法：將72例用利培酮( n=36)或奮迺靜( n=36)治療療效欠佳的穩定期精神分裂癥患者分彆添加米氮平治療12週,治療期間用暘性和陰性癥狀量錶(PANSS)和臨床整體印象嚴重程度量錶( CGI-S)評價患者的臨床療效,用副反應量錶評價患者的不良反應( TESS)。結果：至12週末,米氮平聯閤利培酮或奮迺靜可顯著改善患者的PANSS總量錶分(PANSS-T),PANSS暘性癥狀分量錶分(PANSS-P)和PANSS陰性癥狀分量錶分(PANSS-N),效應量(ES)分彆為1.0、0.8和0.8。但治療6週後,前者對患者的暘性癥狀改善不明顯(P>0.05),後者對患者的陰性癥狀改善不明顯(P>0.05)。兩組患者的不良反應相似。結論：米氮平聯閤利培酮對患者的陰性癥狀改善明顯,聯閤奮迺靜對患者的暘性癥狀改善較明顯,這一結果仍需大量的隨機雙盲研究確定。
목적：：탐구미담평연합불동항정신병약물치료은정기정신분렬증환자적결과。방법：장72례용리배동( n=36)혹강내정( n=36)치료료효흠가적은정기정신분렬증환자분별첨가미담평치료12주,치료기간용양성화음성증상량표(PANSS)화림상정체인상엄중정도량표( CGI-S)평개환자적림상료효,용부반응량표평개환자적불량반응( TESS)。결과：지12주말,미담평연합리배동혹강내정가현저개선환자적PANSS총량표분(PANSS-T),PANSS양성증상분량표분(PANSS-P)화PANSS음성증상분량표분(PANSS-N),효응량(ES)분별위1.0、0.8화0.8。단치료6주후,전자대환자적양성증상개선불명현(P>0.05),후자대환자적음성증상개선불명현(P>0.05)。량조환자적불량반응상사。결론：미담평연합리배동대환자적음성증상개선명현,연합강내정대환자적양성증상개선교명현,저일결과잉수대량적수궤쌍맹연구학정。
Objective:To probe outcomes of Mirtazapine augmented with different types of antipsychotics in treatment of stabi-lized schizophrenics. Methods:72 stabilized schizophrenic patients sub-optimally responsive to Risperidone (n=36) or Perphenazine (n=36) were assigned to an augmentative treatment with mirtazapine for 12 weeks, respectively. During the treatment, positive and negative syndrome scale ( PANSS) , clinical global impression-severity ( CGI-S) scale and treatment emergent symptom scale ( TESS) were used to evaluate efficacy and adverse effects, respectively. Results:At the end of 12th week, the PANSS total scale (PANSS-T) score, PANSS positive subscale ( PANSS-P) score and PANSS negative subscale ( PANSS-N) score of the patients treated with Mir-tazapine combined with Risperidone or Perphenazine were 1. 0, 0. 8 and 0. 8, respectively; however, the improvement of positive symptoms was made not significantly in the former group 6 weeks after the treatment and nor did with that of negative symptoms in the latter group (P>0. 05). The adverse effects were similar between the two groups. Conclusions:Risperidone combined with Mirtazap-ine improve the negative symptoms more significantly and Perphenazine combined with Mirtazapine improve the positive symptoms more significantly;however, these findings still need large randomized, double-blind controlled trials to be confirmed.
